BioSpace News Archive

HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) is pleased to announce the appointment of Trent MacDonald to its executive leadership team in the acting role of Chief Financial Officer, effective today

Vivos Therapeutics, Inc. (“Vivos”) , a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. Application has been made for listing the common st

- Phase 3 data from INNO2VATE program in dialysis and PRO2TECT program in non-dialysis accepted for oral presentation - Ten additional abstracts accepted - Company to host investor briefing webcast at 4:10 p.m. ET on October 23, 2020 [09-October-2020] CAMBRIDGE, Mass. , Oct. 9, 2020 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) toda

With a goal to reduce the amount of local anesthetic used for their continuous peripheral nerve blocks, the surgeons and anesthesiologists at Audubon Surgery Center in Colorado Springs, CO may have found a solution in Nimbus II PainPRO’s Programmed Intermittent Bolus (PIB) feature

Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM) is a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications

Zyno Solutions, experts in providing intelligent IV infusion systems, will feature the Nimbus™ Ambulatory Infusion Pump and the Z-800F Infusion Pump at this year’s Immunoglobulin National Society (IgNS) Virtual Conference on October 22-26.

LeMaitre Vascular, Inc. announced that it will release its third quarter 2020 financial results on Thursday, October 29, 2020, after the market close.

Sorrento Therapeutics, Inc. released details about its upcoming COVID-19 Pipeline Update call and webcast on October 13th, 2020.

Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA). The committees met to discuss ALKS 3831 (olanzapine/samidorphan), an inves

Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers along the Gulf Coast that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by Hurricane Delta.